London-based health tech startup Bioniq, known for creating personalized supplements based on blood biomarker data, has successfully closed a €13.7 million ($15 million) Series B funding round. This round, led by HV Capital and Unbound, brings Bioniq’s valuation to €68.73 million ($75 million).